10 analysts have expressed a variety of opinions on Marinus Pharma (NASDAQ:MRNS) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
5
2
3
0
0
Last 30D
1
0
0
0
0
1M Ago
2
1
2
0
0
2M Ago
1
0
0
0
0
3M Ago
1
1
1
0
0
Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.8, a high estimate of $28.00, and a low estimate of $2.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 20.0%.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of Marinus Pharma's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Douglas Tsao
HC Wainwright & Co.
Lowers
Buy
$11.00
$27.00
Joon Lee
Truist Securities
Lowers
Buy
$10.00
$25.00
Brian Skorney
Baird
Lowers
Neutral
$2.00
$20.00
Douglas Tsao
HC Wainwright & Co.
Maintains
Buy
$27.00
-
Brian Abrahams
RBC Capital
Lowers
Sector Perform
$3.00
$24.00
Charles Duncan
Cantor Fitzgerald
Maintains
Overweight
$28.00
-
Douglas Tsao
HC Wainwright & Co.
Maintains
Buy
$27.00
-
Jay Olson
Oppenheimer
Maintains
Perform
$9.00
$9.00
Brian Abrahams
RBC Capital
Maintains
Outperform
$24.00
-
Douglas Tsao
HC Wainwright & Co.
Maintains
Buy
$27.00
-
Key Insights:
Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether ...Full story available on Benzinga.com
Related tickers: MRNS.
Read Full Article